• Sixty percent of patients with BRAF-mutant melanomas responded to BRAF inhibitor despite a concurrent MEK1 mutation. • Theory was tested in single- and double-mutant tumors.
• Metastases increased in mice with breast cancer and arthritis. • Mast cells one of the major underlying causes of metastases. • Therapies could be developed to decrease metastases.
• Radiation therapy did not add benefit for patients with luminal A subtype. • Patients with all other breast cancer subtypes benefited from radiation therapy. • Routine testing for biomarker Ki-67 recommended for patients with breast cancer.
• Activation of protein translation linked to more aggressive node-positive disease. • Markers identified are regulated by PI3K/mTOR signaling pathway.
• Risk increased as the duration of hormone therapy use increased. • Death rate from breast cancer did not increase with hormone therapy use.
• African-American women had more difficulty clearing HPV infection. • They were nearly twice as likely to have an abnormal Pap test. • Disparities may be attributed to biological determinants of HPV immune response.
• Different mutations in the same cancer gene affected treatment response. • Type 2 EGFR inhibitors may be more effective against glioblastoma.
• Prostate cancer-specific radiotracer designed to highlight prostate cancer. • Imaging agent helped to identify bone metastases. • Technology could allow physicians to monitor treatment efficacy.
• Low oxygen (hypoxia) predicts prostate cancer recurrence after radiotherapy. • Measuring prostate cancer hypoxia could help identify the best treatment for patients. • New treatments that target prostate cancer hypoxia could improve patient outcome.
• Drug combination superior to cancer drug alone. • Data emphasize importance of understanding genetic mutations. • Combination could be effective treatment for BRAF-mutant melanoma.
• Patients with pancreatic cancer often have a high prevalence of diabetes. • Metformin was linked with a nearly twofold higher two-year survival rate. • Patients prescribed metformin had a 32 percent reduced risk for death.
• Agent acts against mTOR to prevent lesion progression. • Oral cancer incidence reduced by 70 to 90 percent. • Results are part of increasing evidence of metformin’s protective effect.
• Metformin activity occurs primarily in the liver. • Drug is safe and well-tolerated in patients with diabetes.
• Ki67 is a protein that indicates cancer cell growth. • Vitamin D increased prostate tissue calcitriol levels, which lowered Ki67.
• Selumetinib controlled the disease in 81 percent of patients. • Median progression-free survival was 11 months. • Patients experienced minimal side effects.
• EWS is the second most common bone malignancy in children and adolescents. • Combination therapy efficacious against chemotherapy-resistant EWS. • The combination was safe, with manageable adverse events.
• Pazopanib achieved the primary endpoint of response. • Interleukin-8 may be an indicator of tumor resistance and poor survival. • Data need further validation in a large patient population.
• Preliminary data show diabetes drug reduced cancer growth. • No grade 3 adverse events reported. • Findings have implications for men with diabetes, prediabetes.
• Galeterone targets prostate cancer through three distinct mechanisms. • The drug was well tolerated and safe at all doses tested. • Efficacy was demonstrated by PSA decreases and tumor reduction.
• Drugs previously considered too toxic for human use. • Cancer stem cells were a target of these agents. • Study by Stand Up To Cancer Dream Team published in Cancer Cell.
Alan D. D’Andrea, M.D., the Alvan T. and Viola D. Fuller American Cancer Society professor of radiation oncology at the Dana-Farber Cancer Institute and Harvard Medical School, will receive the 52nd Annual AACR G.H.A. Clowes Memorial Award for his work in understanding cancer survival and progression, which has included milestones such as cloning the erythropoietin receptor and discovering the Fanconi anemia family of proteins involved in maintaining DNA stability.
Recipient of the Pezcoller Foundation-AACR International Award for Cancer Research.
The American Association for Cancer Research will award Bert Vogelstein, M.D., with the Eighth Annual AACR-Irving Weinstein Foundation Distinguished Lectureship at the AACR Annual Meeting 2012, held here March 31 - April 4.
Lawrence H. Einhorn, M.D., distinguished professor of medicine and the Lance Armstrong Foundation chair in oncology at the Indiana University School of Medicine, and a physician-researcher at Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Ind., will be awarded the 17th Annual AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research at the AACR Annual Meeting 2012, held here March 31 – April 4.
• Higher levels of PFKFB4 found in metastatic prostate tumors. • Depletion of this gene inhibited tumor growth in laboratory models. • Results suggest a potential new target for therapy.
• Assay could direct treatment options for triple-negative breast cancer. • Accumulations of telomere AI predicted sensitivity to therapy.
The American Association for Cancer Research will recognize Stephen W. Fesik, Ph.D., with the 2012 AACR Award for Outstanding Achievement in Chemistry in Cancer Research at the AACR Annual Meeting 2012, held here March 31 – April 4.
A Team from The Institute of Cancer Research and The Royal Marsden Hospital U.K. Receives the AACR’s Sixth Annual Team Science Award
The American Association for Cancer Research will recognize Yibin Kang, Ph.D., associate professor of molecular biology in the department of molecular biology at Princeton University and member of the Cancer Institute of New Jersey, with the 32nd Annual AACR Award for Outstanding Achievement in Cancer Research at the AACR Annual Meeting 2012, held here March 31 – April 4.
The members of the American Association for Cancer Research have elected Charles L. Sawyers, M.D., as their president-elect for 2012-2013. Sawyers is chair of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center and a Howard Hughes Medical Institute investigator. Additionally, he is a professor in the Cell and Developmental Biology Program and the Department of Medicine at the Joan & Sanford Weill Graduate School of Medical Sciences of Cornell University.
Two awards total $1. 2 million to advance pancreatic cancer research.
• Cadmium is a toxic metal found in many fertilizers. • Study included more than 55,000 women. • Whole grains and vegetables may counteract the effects.
Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI), along with the American Association for Cancer Research (AACR), call upon the cancer research community to submit Letters of Intent for a new Dream Team — the SU2C-CRI Cancer Immunology Translational Research Dream Team.
• Nab-paclitaxel appears to enhance gemcitabine activity. • Study also shows the potential value of a time-delay administration. • Combination treatment regimen already in late-stage phase III clinical trial.
• Inhibition of VEGF increased c-MET expression in tumors. • Invasion and metastasis were blocked by inhibition of VEGF plus c-MET. • Dual VEGF/c-MET inhibitors are in late-stage clinical trials.
The American Association for Cancer Research’s newest journal, Cancer Discovery, has received a 2011 American Publishers Award for Professional and Scholarly Excellence (PROSE Award). Cancer Discovery received this award for “Best New Journal in Science, Technology and Medicine.”
Foremost international meeting highlights breakthroughs in cancer research. Chicago, Ill. , March 31 – April 4, 2012.
The American Association for Cancer Research supports World Cancer Day on Saturday, Feb. 4, and the efforts of the Union for International Cancer Control (UICC) to bring the looming world cancer crisis to the forefront by urging the public, government leaders and health policy makers to take proactive steps in the global fight against cancer.
• Findings suggest the effects of food may be more complex. • Adverse effect observed in younger women.
Briefing to feature leading researchers, congress members and cancer survivors.
• A20 E3 ubiquitin ligase could be a therapeutic target. • Targeting this ligase may overcome TRAIL resistance. • No current therapy available for glioblastoma.
The American Association for Cancer Research is currently accepting applications for the 2012 Caring for Carcinoid Foundation-AACR Grants for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research. This is the second year of the AACR’s grant-giving partnership with the Caring for Carcinoid Foundation.
• Changes to specific proteins can lead to tumor growth and development. • Glioblastoma patients often have a poor prognosis. • Understanding molecular mechanisms can lead to new treatments.
• Novel Hsp90 inhibitor shows activity in slowing KRAS-mutant NSCLC tumor cell growth. • Use with traditional chemotherapy resulted in increased cancer cell death. • Phase 2b/3 trial combined with docetaxel underway.
• Smokers are more likely to have molecular features of cancerization in the large airway epithelium. • Smokers with COPD had significant changes in the small airway epithelium. • Findings could lead to development of a diagnostic test.
• Survival rates were “unsatisfactory” in patients with NSCLC and a KRAS mutation. • “Great need” exists for new treatment combinations in this patient population.
• Certain genes can be used to define the lung tumor’s type and ability to clone. • Genetic status information might be used to presume genetic background.
• Extremely sensitive methodology can analyze a DNA sample size as small as three cells. • Analysis method may be able to detect mutations in CTCs from patients with NSCLC. • Method could help track progress of NSCLC and guide choice of targeted therapies.
• Early results reported from a preclinical mouse study. • Combination included an antiestrogen and aromatase inhibitor. • Effect seen before and after precancerous development.
• Progress made in identifying ways lung cancer develops in never-smokers. • New mutations and pathway changes not found in patients who smoked. • Ten percent of lung cancers are found in patients who never smoked.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right